Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 3 18Phase 4 8Phase 1 6Phase 2/3 2

Status

Completed 6

Sponsor Class

OTHER 22INDUSTRY 6NIH 4NETWORK 2

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 2Thoracic 1Sarcoma 1

Conditions

Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 301Paclitaxel 206Carboplatin 199Gemcitabine 173Cisplatin 138Docetaxel 137Cyclophosphamide 135Nivolumab 129Bevacizumab 118Injections 111fludarabine 95atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 70Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × pegfilgrastim × Clear all
NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Hoffmann-La Roche

Phase 1 Completed
83 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01840579 2021-06-22

MK-3475-011

Merck Sharp & Dohme LLC

Phase 1 Completed
57 enrolled 60 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT01214629 2018-08-06

A Study for Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
54 enrolled 23 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01214642 2018-08-06

A Dose-Escalation Study for Patients With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
63 enrolled 23 charts
Tumor-Agnostic

Neoplasms

NCT03376503 2017-12-19

Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 1 Completed
24 enrolled
Breast

Breast Neoplasms

NCT01585649 2016-05-18

PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
21 enrolled
Sarcoma

Rhabdomyosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡